{
  "title": "M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nGeneral Information on Participation in CBRNE Testing\n2\nDeveloping Claims Based on Participation in CBRNE Testing\n1\n.\nGeneral Information on Participation in CBRNE Testing\nIntroduction\nThis topic contains general information on participation in CBRNE testing, including\nbackground on CBRNE testing\nestablishing CBRNE test participation\nCBRNE testing and toxic exposure risk activity (TERA)\naction to take when the Veteran claims participation in CBRNE testing but does not claim a disability\n, and\nend product (EP) control procedures for claims based on CBRNE testing\n.\nChange Date\nMarch 17, 2025\nVIII.iii.5.A.1.a\n.\nBackground on CBRNE Testing\nAs part of its efforts to ensure the United States military could adequately protect its service members from possible wartime exposures to chemical warfare agents, the military conducted chemical, biological, radiological, nuclear, and explosives (CBRNE) testing and often used service members as volunteer test participants.\nGenerally, CBRNE testing began during the World War II era and was discontinued in 1975. Precise information on the number of tests, experiments, and participants is not available.  The Department of Defense (DoD) has identified specific locations and tests that occurred; however, a full list of testing locations and participants is not known due to record keeping practices of that era.\nBased on DoD research, CBRNE testing is known to have occurred at the following locations:\nEdgewood Arsenal between 1955 and 1975\nFort (Ft.) Detrick between 1943 and 1973\nPine Bluff\nFt. Bragg in 1958\nFt. Benning in 1960\nRocky Mountain Arsenal, and\nDugway Proving Ground.\nImportant\n:  While the locations and dates listed above are known sites based on DoD’s research of records, it is possible testing occurred at other military installations on dates outside of those listed.  Specific allegations of test participation conducted after 1975 or at a location not listed above should be considered on a facts-found basis by following the procedures outlined in\nM21-1, Part VIII, Subpart iii, 5.A.2.b\n.\nReference\n:  For more information on CBRNE testing, see the\nMilitary Health System Cold War website\n.\nVIII.iii.5.A.1.b\n.\nEstablishing CBRNE Test Participation\nParticipation in CBRNE testing\nmeans the Veteran was a medical research participant or otherwise exposed to substances during CBRNE testing.  Service at a specific location alone does not establish CBRNE test participation.  The evidence must show participation in a specific research project or exposure to a test. In most cases, participation should be documented in the Chemical Biological Warfare Exposure System Registry in the Individual Longitudinal Exposure Record (ILER); however, test participation may also be documented in service records.\nExceptions\n:  The following exposure claims are not considered CBRNE claims as they have their own unique policies and procedures:\nShipboard Hazards and Defense (SHAD) Project as defined in\nM21-1, Part VIII, Subpart iii, 6.A.1.a\n, and\nmustard gas and Lewisite exposure as defined in\nM21-1, Part VIII, Subpart iii, 3.A.1.a\n.\nReference\n:  For more information on CBRNE testing, see the\nMilitary Health System Cold War website\n.\nVIII.iii.5.A.1.c\n.\nCBRNE Testing and TERA\nCBRNE testing is a type of toxic exposure risk activity (TERA). It must be researched and documented when explicitly claimed or implicitly raised by following the TERA procedures outlined in the\nSergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022 Implementation Standard Operating Procedure (SOP)\nas well as the CBRNE procedures below.\nVIII.iii.5.A.1.d\n.\nAction to Take When the Veteran Claims Participation in CBRNE Testing but Does Not Claim a Disability\nA claim is not substantially complete if a Veteran alleges participation in CBRNE testing during service, but does not claim service connection (SC) for a specific disability.  In cases such as these, follow the procedures for handling an incomplete application at\nM21-1, Part II, Subpart iii, 1.C.2.b and c\n.\nVIII.iii.5.A.1.e\n.\nEP Control Procedures for Claims Based on CBRNE Testing\nUpon receipt of a substantially complete CBRNE claim for SC, establish a traditional rating end product (EP) (for example, 010, 110, 020) and affix the\nChemBio\nspecial issue indicator to the relevant contention(s).\nReferences\n:  For more information on\nEP control, see\nM21-4, Appendix B, Section II\n, and\nspecial issues, see\nM21-4, Appendix E\n.\n2\n.\nDeveloping Claims Based on Participation in CBRNE Testing\nIntroduction\nThis topic contains information on developing claims based on CBRNE testing, including\nresearching CBRNE in ILER\nprocedure for verifying participation in CBRNE testing\n, and\ninformation to include in examination and/or medical opinion requests for claims based on CBRNE testing\n.\nChange Date\nMarch 17, 2025\nVIII.iii.5.A.2.a\n.\nResearching CBRNE in ILER\nILER is a joint DoD and Department of Veterans Affairs (VA) web-based application that provides the ability to link a Veteran to military exposures and/or deployments.\nClaims processors must utilize ILER to conduct preliminary research regarding claimed in-service chemical and biological agent testing-related exposures.\nImportant\n:  ILER access should be requested in advance of receipt of a claim based on exposure in order to ensure that claims processing is not unnecessarily delayed.\nReference\n:  For more information on ILER and how to obtain access, see the\nILER Guidance\n.\nVIII.iii.5.A.2.b\n.\nProcedure for Verifying Participation in CBRNE Testing\nFollow the steps in the table below to verify participation in CBRNE testing.\nImportant\n:\nBecause DoD is declassifying tests on an irregular schedule, this verification must be done\nevery\ntime testing participation is alleged, even if previous attempts to verify participation were negative.\nStep\nAction\n1\nIs CBRNE testing participation documented in ILER?\nExample\n:\nIf\nyes\n,\nensure the Individual Exposure Summary/ILER response is documented in the electronic claims folder (eFolder) in accordance with the\nILER Guidance\ndocument CBRNE testing participation and all other TERA on the\nTERA Memorandum\n, and\nfollow the examination guidance in\nM21-1, Part VIII, Subpart iii, 5.A.2.c\n.\nIf\nno\n, go to the next step.\ndocument the negative ILER result in accordance with the\nILER Guidance\n, and\ngo to the next step.\n2\nEnsure receipt of the Veteran’s military records.  Review all available military records.  Is test participation shown?\nIf\nyes\n,\ndocument CBRNE testing participation and all other TERA on the\nTERA Memorandum\n, and\nfollow the examination guidance in\nM21-1, Part VIII, Subpart iii, 5.A.2.c\n.\nIf\nno\n,\ndo not concede CBRNE testing participation, and\nfollow procedures to research and document any other TERA participation.\nReference\n:  For more information on TERA procedures, see the\nPACT Act Implementation SOP\n.\nVIII.iii.5.A.2.c\n.\nInformation to Include in Examination and/or Medical Opinion Requests for Claims Based on CBRNE Testing\nThere are no presumptive conditions or disabilities recognized as common to CBRNE testing. Since participation in CBRNE testing is considered a TERA, complete a\nTERA Memorandum\nand schedule all appropriate examinations with medical opinions. When requesting an examination based on CBRNE test participation, follow the TERA examination request procedures, and include the following:\na request for a TERA medical opinion regarding any relationship between the claimant’s current disability and exposure to agents, simulants, tracers, or antidotes used in the test(s) the Veteran was involved in, as well as any other documented TERA participation for the Veteran, and\nidentification of relevant evidence for the examiner’s review, including the exposure information obtained from ILER, if available, or evidence of test participation identified under\nM21-1, Part VIII, Subpart iii, 5.A.2.b\n.\nImportant\n:  When requesting an examination and/or medical opinion for claims based on CBRNE testing, ensure the examiner is provided with the claims folder for consideration.\nReferences\n:  For more information on\nTERA examination request procedures, see the\nPACT Act Implementation SOP\n, and\nidentifying relevant evidence for the examiner’s review, see\nM21-1, Part IV, Subpart i, 2.A.8.d\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><div class=\"ng-scope\" style=\"text-align: right\"> <span style=\"font-size: 11px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177456\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section C - Rating Claims for Disabilities Associated With Radiation Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177456/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-C-Rating-Claims-for-Disabilities-Associated-With-Radiation-Exposure\">&lt;-- Previous Section</a>  <a articleid=\"554400000177458\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section B - Rating Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177458/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-B-Rating-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">Next Section --&gt;</a></span></span></div><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"height: 8px; width: 15px; vertical-align: top\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In This Section </span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This section contains the following topics:</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 77px; padding: 1px;\"><div style=\"text-align: center\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Topic</span></span></strong></div></th><th scope=\"col\" style=\"width: 432px; padding: 1px;\"><div style=\"text-align: center\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Topic Name</span></span></strong></div></th></tr></thead><tbody><tr><td style=\"text-align: center; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"padding: 1px;\"><div><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">General Information on Participation in CBRNE Testing</span></span></a></div></td></tr><tr><td style=\"text-align: center; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"padding: 1px;\"><div><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Developing Claims Based on Participation in CBRNE Testing</span></span></a></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"><span style=\"font-size: 14px\"> <br/><br/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 16px\">1<a id=\"1\" name=\"1\">. </a>  General Information on Participation in CBRNE Testing</span></span></span></span></h2><div class=\"ng-scope\"><br/><span style=\"font-size: 14px\"> </span></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">      </span></span><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains general information on participation in CBRNE testing, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\">background on CBRNE testing</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\">establishing CBRNE test participation</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1c\" target=\"_self\">CBRNE testing and toxic exposure risk activity (TERA)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1d\" target=\"_self\">action to take when the Veteran claims participation in CBRNE testing but does not claim a disability</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1e\" target=\"_self\">end product (EP) control procedures for claims based on CBRNE testing</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">March 17, 2025</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.1.a<a id=\"1a\" name=\"1a\">.</a>  Background on CBRNE Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">As part of its efforts to ensure the United States military could adequately protect its service members from possible wartime exposures to chemical warfare agents, the military conducted chemical, biological, radiological, nuclear, and explosives (CBRNE) testing and often used service members as volunteer test participants.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Generally, CBRNE testing began during the World War II era and was discontinued in 1975. Precise information on the number of tests, experiments, and participants is not available.  The Department of Defense (DoD) has identified specific locations and tests that occurred; however, a full list of testing locations and participants is not known due to record keeping practices of that era.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Based on DoD research, CBRNE testing is known to have occurred at the following locations: </span></span></div><ul><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Edgewood Arsenal between 1955 and 1975</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Fort (Ft.) Detrick between 1943 and 1973</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Pine Bluff</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Ft. Bragg in 1958</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Ft. Benning in 1960</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Rocky Mountain Arsenal, and</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Dugway Proving Ground.</span></span></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>Important</em></strong>:  While the locations and dates listed above are known sites based on DoD’s research of records, it is possible testing occurred at other military installations on dates outside of those listed.  Specific allegations of test participation conducted after 1975 or at a location not listed above should be considered on a facts-found basis by following the procedures outlined in <a href=\"#2b\" target=\"_self\">M21-1, Part VIII, Subpart iii, 5.A.2.b</a>.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Reference</i></b>:  For more information on CBRNE testing, see the <a href=\"https://health.mil/Military-Health-Topics/Health-Readiness/Environmental-Exposures/Cold-War\" target=\"_blank\">Military Health System Cold War website</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.1.b<a id=\"1b\" name=\"1b\">.</a>  Establishing CBRNE Test Participation</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Participation in CBRNE testing</i></b> means the Veteran was a medical research participant or otherwise exposed to substances during CBRNE testing.  Service at a specific location alone does not establish CBRNE test participation.  The evidence must show participation in a specific research project or exposure to a test. In most cases, participation should be documented in the Chemical Biological Warfare Exposure System Registry in the Individual Longitudinal Exposure Record (ILER); however, test participation may also be documented in service records.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Exceptions</i></b>:  The following exposure claims are not considered CBRNE claims as they have their own unique policies and procedures:</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Shipboard Hazards and Defense (SHAD) Project as defined in <a articleid=\"554400000177459\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 6, Section A - Developing Claims Based on Participation in Project Shipboard Hazard and Defense (SHAD)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177459/M21-1-Part-VIII-Subpart-iii-Chapter-6-Section-A-Developing-Claims-Based-on-Participation-in-Project-Shipboard-Hazard-and-Defense-SHAD\">M21-1, Part VIII, Subpart iii, 6.A.1.a</a>, and</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">mustard gas and Lewisite exposure as defined in <a articleid=\"554400000177452\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 3, Section A - Developing Claims for Service Connection (SC) for Disabilities Resulting From Exposure to Mustard Gas or Lewisite\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177452/M21-1-Part-VIII-Subpart-iii-Chapter-3-Section-A-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-From-Exposure-to-Mustard-Gas-or-Lewisite\">M21-1, Part VIII, Subpart iii, 3.A.1.a</a>.</span></span></div></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Reference</i></b>:  For more information on CBRNE testing, see the <a href=\"https://health.mil/Military-Health-Topics/Health-Readiness/Environmental-Exposures/Cold-War\" target=\"_blank\">Military Health System Cold War website</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.1.c<a id=\"1c\" name=\"1c\">.</a>  CBRNE Testing and TERA</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">CBRNE testing is a type of toxic exposure risk activity (TERA). It must be researched and documented when explicitly claimed or implicitly raised by following the TERA procedures outlined in the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022 Implementation Standard Operating Procedure (SOP)</i></a> as well as the CBRNE procedures below.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.1.d<a id=\"1d\" name=\"1d\">.</a>  Action to Take When the Veteran Claims Participation in CBRNE Testing but Does Not Claim a Disability</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A claim is not substantially complete if a Veteran alleges participation in CBRNE testing during service, but does not claim service connection (SC) for a specific disability.  In cases such as these, follow the procedures for handling an incomplete application at <a articleid=\"554400000174872\" articlename=\"M21-1, Part II, Subpart iii, Chapter 1, Section C - Screening Applications for Substantial Completeness and Notification Requirements\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174872/M21-1-Part-II-Subpart-iii-Chapter-1-Section-C-Screening-Applications-for-Substantial-Completeness-and-Notification-Requirements\">M21-1, Part II, Subpart iii, 1.C.2.b and c</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.1.e<a id=\"1e\" name=\"1e\">.</a>  EP Control Procedures for Claims Based on CBRNE Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Upon receipt of a substantially complete CBRNE claim for SC, establish a traditional rating end product (EP) (for example, 010, 110, 020) and affix the <em>ChemBio</em> special issue indicator to the relevant contention(s).</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">EP control, see <a articleid=\"554400000011474\" articlename=\"Appendix B. End Product (EP) Codes\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000011474/Appendix-B-End-Product-EP-Codes\">M21-4, Appendix B, Section II</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">special issues, see  <a articleid=\"554400000179710\" articlename=\"Appendix E. Index of Corporate Flashes and Special Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000179710/Appendix-E-Index-of-Corporate-Flashes-and-Special-Issues\">M21-4, Appendix E</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\"><br/> </div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Developing Claims Based on Participation in CBRNE Testing</span></span></h2><div class=\"ng-scope\"><br/><span style=\"font-size: 14px\"> </span></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">      </span></span><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information on developing claims based on CBRNE testing, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2a\" target=\"_self\">researching CBRNE in ILER</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2b\" target=\"_self\">procedure for verifying participation in CBRNE testing</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2c\" target=\"_self\">information to include in examination and/or medical opinion requests for claims based on CBRNE testing</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">March 17, 2025</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.2.a<a id=\"2a\" name=\"2a\">.</a>  Researching CBRNE in ILER</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">ILER is a joint DoD and Department of Veterans Affairs (VA) web-based application that provides the ability to link a Veteran to military exposures and/or deployments.    </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Claims processors must utilize ILER to conduct preliminary research regarding claimed in-service chemical and biological agent testing-related exposures. </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Important</i></b>:  ILER access should be requested in advance of receipt of a claim based on exposure in order to ensure that claims processing is not unnecessarily delayed.</span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Reference</i></b></span>:  For more information on ILER and how to obtain access, see the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>ILER Guidance</i></a>.</span><i> </i></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.A.2.b<a id=\"2b\" name=\"2b\">.</a>  Procedure for Verifying Participation in CBRNE Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Follow the steps in the table below to verify participation in CBRNE testing.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  </span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Because DoD is declassifying tests on an irregular schedule, this verification must be done <em>every</em> time testing participation is alleged, even if previous attempts to verify participation were negative. </span></span></div><div></div></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides instructions afters attempting to verify participation in CBRNE testing.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Is CBRNE testing participation documented in ILER?</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><b><i>Example</i></b>:</span></span></div><div></div><div><img alt=\"This is an image of CBRNE testing participation documented in ILER.\" id=\"7ce7b9e9-394d-4487-831d-e4143d17a8ff\" name=\"VIII.iii.5.A.png\" src=\"/system/ws/v11/media/image/5544/7ce7b9e9-394d-4487-831d-e4143d17a8ff\" style=\"width:624px;height:491px\"/></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If <em>yes</em>,</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">ensure the Individual Exposure Summary/ILER response is documented in the electronic claims folder (eFolder) in accordance with the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>ILER Guidance</i></a></span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">document CBRNE testing participation and all other TERA on the <i>TERA Memorandum</i>, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">follow the examination guidance in <a href=\"2c\">M21-1, Part VIII, Subpart iii, 5.A.2.c</a>.</span></span></div></li></ul></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If <em>no</em>, go to the next step.</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">document the negative ILER result in accordance with the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>ILER Guidance</i></a>, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">go to the next step.</span></span></div></li></ul></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Ensure receipt of the Veteran’s military records.  Review all available military records.  Is test participation shown?</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>yes</em>,</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">document CBRNE testing participation and all other TERA on the <i>TERA Memorandum</i>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">follow the examination guidance in <a href=\"#2c\" target=\"_self\">M21-1, Part VIII, Subpart iii, 5.A.2.c</a>.</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>no</em>,</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">do not concede CBRNE testing participation, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">follow procedures to research and document any other TERA participation.</span></span></div></li></ul></li></ul></td></tr></tbody></table></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on TERA procedures, see the <em><a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\">PACT Act Implementation SOP</a>.</em></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">VIII.iii.5.A.2.c<a id=\"2c\" name=\"2c\">.</a>  Information to Include in Examination and/or Medical Opinion Requests for Claims Based on CBRNE Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"> </span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">There are no presumptive conditions or disabilities recognized as common to CBRNE testing. Since participation in CBRNE testing is considered a TERA, complete a <i>TERA Memorandum</i> and schedule all appropriate examinations with medical opinions. When requesting an examination based on CBRNE test participation, follow the TERA examination request procedures, and include the following: </span></span><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><ul><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">a request for a TERA medical opinion regarding any relationship between the claimant’s current disability and exposure to agents, simulants, tracers, or antidotes used in the test(s) the Veteran was involved in, as well as any other documented TERA participation for the Veteran, and </span></span></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">identification of relevant evidence for the examiner’s review, including the exposure information obtained from ILER, if available, or evidence of test participation identified under <a href=\"#2b\" target=\"_self\">M21-1, Part VIII, Subpart iii, 5.A.2.b</a>.</span></span></div></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>Important</em></strong>:  When requesting an examination and/or medical opinion for claims based on CBRNE testing, ensure the examiner is provided with the claims folder for consideration. </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><span style=\"font-size:14px;\"><span style=\"font-family: arial, helvetica, sans-serif\">TERA examination request procedures, see the <em><a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\">PACT Act Implementation SOP</a></em>, and</span></span></li><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">identifying relevant evidence for the examiner’s review, see <a articleid=\"554400000180498\" articlename=\"M21-1, Part IV, Subpart i, Chapter 2, Section A - Examination Requests Overview\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180498/M21-1-Part-IV-Subpart-i-Chapter-2-Section-A-Examination-Requests-Overview\">M21-1, Part IV, Subpart i, 2.A.8.d</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><div style=\"text-align: right\"> <span style=\"font-size: 11px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177456\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section C - Rating Claims for Disabilities Associated With Radiation Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177456/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-C-Rating-Claims-for-Disabilities-Associated-With-Radiation-Exposure\">&lt;-- Previous Section</a>  <a articleid=\"554400000177458\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section B - Rating Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177458/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-B-Rating-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">Next Section --&gt;</a></span></span></div><p><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><span margin-left:=\"\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></span></span></span></span></span></p></div><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "https://health.mil/Military-Health-Topics/Health-Readiness/Environmental-Exposures/Cold-War",
    "https://vbaw.vba.va.gov/bl/21/pact.htm"
  ],
  "scraped_at": "2025-06-16T22:58:46.414556",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177458/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-B-Rating-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing"
}